← All trials
NCT04866485
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 14, 2021
- Primary completion
- Feb 28, 2023
- Completion date
- Feb 28, 2023
- First posted
- Apr 29, 2021
- Last posted
- Apr 29, 2021
- Enrollment
- 66
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harbour BioMed Co. Ltd.Lead sponsor
- Jiao Tong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.